Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: poodle who wrote (491)	2/9/1999 1:37:00 AM
From: Mike McFarland	Respond to of 4474

The discussion is still over my head, but I can wait until the share price does what I want it to do...between now and then the only thing that is required is patience. Perhaps understanding the nature of this convertible issue is not actually required...in the long run. In May 1994 BusinessWeek ran an article about James Wilson and his Institute for Human Gene Therapy...and Penn. This must have been pre- Genovo and certainly pre-Ariad. You can purchase fifty articles for $20 from the BW archive...not too bad, so I grabbed it. Here is the smallest snippet I can provide and not risk the wrath of the BW lawyers;-) "Gene therapy is too expensive to do academically" said Dr. Ronald G. Crystal, chief of pulmonary medicine at New York Hospital-Cornell Medical Center and co- founder of startup GenVec in Rockville, Md. Well all the pieces are teamed up together now, and maybe Wilson's ambition and spending had a lot to do with it. The Science article ran less than five years after the article in BW--if a person read the blurb in BusinessWeek five years ago, he'd have said "not in my lifetime". Good night.